enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. AMAG Pharmaceuticals (AMAG) Upgraded to Buy: Here's Why - AOL

   www.aol.com/news/amag-pharmaceuticals-amag...

   AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3. AMAG (AMAG) to be Acquired by Covis Group for $647 Million - AOL

   www.aol.com/news/amag-amag-acquired-covis-group...

   For premium support please call: 800-290-4726 more ways to reach us

4. AMAG Sees Hammer Chart Pattern: Time to Buy? - AOL

   www.aol.com/news/amag-sees-hammer-chart-pattern...

   For premium support please call: 800-290-4726 more ways to reach us

5. AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

   www.aol.com/news/amag-sell-women-healthcare...

   For premium support please call: 800-290-4726 more ways to reach us

6. AMAG Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/AMAG_Pharmaceuticals

   AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company was a publicly traded company listed on NASDAQ under the symbol "AMAG" until November 2020 when it was acquired by Covis Pharma.

7. AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected - AOL

   www.aol.com/news/amag-pharmaceuticals-amag-q2...

   For premium support please call: 800-290-4726 more ways to reach us

8. Stock market news live updates: Stocks rise with all eyes on ...

   www.aol.com/finance/stock-market-news-live...

   A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., January 5, 2023. REUTERS/Andrew Kelly (Andrew Kelly / reuters)

9. AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Tops ... - AOL

   www.aol.com/news/amag-pharmaceuticals-amag...

   AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?